Interní Med. 2018; 20(2): 82-84 | DOI: 10.36290/int.2018.015

Hypolipidemic treatment and target values of lipids

MUDr. Ondřej Kyselák¹, prof. MUDr. Vladimír Soška, CSc.^{1, 2}

¹ Oddělení klinické biochemie, FN u sv. Anny v Brně

² II. interní klinika; Biochemický ústav, Lékařská fakulta MU Brno

Hypolipidemics are one of the most frequently prescribed drugs in the world. Last year, the updated guidelines were released:European Guidelines on cardiovascular disease prevention in clinical practice by European Society of Cardiology (ESC) and ESC/EAS (European Atherosclerosis Society) Guidelines for the Management of Dyslipidaemias. Both of them contain changes mainlyin estimation of individual cardiovascular risk and target levels of LDL-cholesterol. Targeting these goals is usually very difficultand often impossible in patients with familial hypercholesterolemia. PCSK9 inhibitors are a new and very potent hypolipidemicsthat should make target LDL-cholesterol levels reachable.

Keywords: dyslipidemia, cardiovascular diseases, LDL cholesterol, triglycerides, statins, PCSK9 inhibitors

Published: May 1, 2018  Show citation